Literature DB >> 7504357

Carrier-mediated release of neurotransmitters.

G Levi1, M Raiteri.   

Abstract

There is growing evidence that neurotransmitters can be released not only by exocytosis but also through the membrane carriers responsible for transmitter reuptake. Giulio Levi and Maurizio Raiteri review the in vitro and in vivo evidence supporting the existence of a carrier-mediated release for different classes of transmitters. While the physiological significance of carrier-mediated release remains speculative, widely used drugs such as sympathomimetic amines, the anorectic drug fenfluramine and some drugs of abuse act in part by stimulating monoamine carrier-mediated release. Moreover, antidepressants known to inhibit monoamine reuptake, can block carrier-mediated release. This mechanism may also come into play in pathological conditions such as ischaemia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504357     DOI: 10.1016/0166-2236(93)90010-j

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  63 in total

Review 1.  Synaptosomes still viable after 25 years of superfusion.

Authors:  L Raiteri; M Raiteri
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

2.  Extracellular protons differentially potentiate the responses of native AMPA receptor subtypes regulating neurotransmitter release.

Authors:  Anna Pittaluga; Daniela Segantini; Marco Feligioni; Maurizio Raiteri
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

Review 3.  Pharmacological and biochemical aspects of GABAergic neurotransmission: pathological and neuropsychobiological relationships.

Authors:  Renê Oliveira Beleboni; Ruither Oliveira Gomes Carolino; Andrea Baldocchi Pizzo; Lissandra Castellan-Baldan; Joaquim Coutinho-Netto; Wagner Ferreira dos Santos; Norberto Cysne Coimbra
Journal:  Cell Mol Neurobiol       Date:  2004-12       Impact factor: 5.046

4.  Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area.

Authors:  M J Nirenberg; J Chan; R A Vaughan; G R Uhl; M J Kuhar; V M Pickel
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

5.  Nonvesicular inhibitory neurotransmission via reversal of the GABA transporter GAT-1.

Authors:  Yuanming Wu; Wengang Wang; Ana Díez-Sampedro; George B Richerson
Journal:  Neuron       Date:  2007-12-06       Impact factor: 17.173

6.  An investigation of the origin of extracellular GABA in rat nucleus accumbens measured in vivo by microdialysis.

Authors:  S E Smith; T Sharp
Journal:  J Neural Transm Gen Sect       Date:  1994

7.  Novel microbiota-related gene set enrichment analysis identified osteoporosis associated gut microbiota from autoimmune diseases.

Authors:  Rong-Rong Cao; Pei He; Shu-Feng Lei
Journal:  J Bone Miner Metab       Date:  2021-08-02       Impact factor: 2.626

8.  GAT-3, a high-affinity GABA plasma membrane transporter, is localized to astrocytic processes, and it is not confined to the vicinity of GABAergic synapses in the cerebral cortex.

Authors:  A Minelli; S DeBiasi; N C Brecha; L V Zuccarello; F Conti
Journal:  J Neurosci       Date:  1996-10-01       Impact factor: 6.167

9.  Interaction of catechol and non-catechol substrates with externally or internally facing dopamine transporters.

Authors:  Ying-Jian Liang; Juan Zhen; Nianhang Chen; Maarten E A Reith
Journal:  J Neurochem       Date:  2009-03-11       Impact factor: 5.372

10.  The metabotropic glutamate receptor 7 (mGluR7) allosteric agonist AMN082 modulates nucleus accumbens GABA and glutamate, but not dopamine, in rats.

Authors:  Xia Li; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2007-11-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.